WO2026022584 - METHODS OF DELAYING DEMENTIA
National phase entry is expected:
Publication Number
WO/2026/022584
Publication Date
29.01.2026
International Application No.
PCT/IB2025/056955
International Filing Date
09.07.2025
Title **
[English]
METHODS OF DELAYING DEMENTIA
[French]
MÉTHODES DE RETARDEMENT DE LA DÉMENCE
Applicants **
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors
SCHWAB, Patrick
TRIASTCYN, Aleksei
POLISKY, Vitaly
LITTMANN, Maria
Priority Data
63/673,946
22.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3081 | |
| EPO | Filing, Examination, Granting | 18579 | |
| Japan | Filing, Examination, Granting | 2646 | |
| South Korea | Filing, Examination, Granting | 3076 | |
| USA | Filing, Examination, Granting | 11590 |
Total:
38,972
Contact Us
Abstract[English]
Described are methods of delaying the onset or progression of dementia or mild cognitive impairment in a subject comprising administering to the subject a Varicella Zoster Virus glycoprotein E (VZV gE) polypeptide or a recombinant nucleic acid encoding a VZV gE polypeptide.[French]
L'invention concerne des méthodes de retardement de l'apparition ou de la progression de la démence ou d'une déficience cognitive légère chez un sujet, comprenant l'administration au sujet d'un polypeptide de glycoprotéine E du virus varicelle-zona (VZV gE) ou d'un acide nucléique recombinant codant pour un polypeptide gE VZV.